Funding to develop new drugs for some of the world’s leading infectious disease killers, such as HIV/AIDS, TB and malaria, reached a record high of US $4 billion in 2018, with private sector investment driving much of the increase, according to the 2019 G-FINDER Report, which tracks such investments globally. However, investments in neglected tropical […] Continue reading ->
Neglected tropical diseases (NTDs) can lead to physical disfiguration, stress and stigmatization, which leave lifelong impacts on the mental health of many of those infected, even after the disease itself is cured.  As the health community prepares to mark the first-ever World NTD Day on 30 January, Nathalie Strub-Wourgaft, director of Neglected Tropical Diseases at […] Continue reading ->
The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading ->
[Drugs for Neglected Diseases Initiative] Geneva, Switzerland (29 November 2019) – The Indian pharmaceutical company Cipla has announced their commitment to price the ground-breaking new product Quadrimune, a “4‑in‑1” treatment for young children with HIV, at below a dollar a day. Quadrimune is currently under review by the US Food and Drug Administration (FDA) for use in children […] Continue reading ->
Efforts to eliminate river blindness, a debilitating parasitic disease that causes vision loss in 1.15 million people, may be threatened by another infection known as African eye worm, according to a modelling study published in Clinical Infectious Diseases. While the World Health Organization has set a target to eliminate river blindness in most African countries […] Continue reading ->
Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading ->
The Drugs for Neglected Diseases Initiative (DNDi) celebrates its 15th anniversary this week, as a non-profit drug R&D organization that sought to create an alternative model for developing drug treatments for the most neglected diseases and the world’s poorest populations. Since DNDi’s launch in 2003, the organization has developed eight new treatments, including the first-ever […] Continue reading ->
Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading ->
[DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading ->